Standards of care for treatment of recurrent glioblastoma--are we there yet?

By Michael Weller, T. Cloughesy, J. Perry, Wolfgang Wick. Neuro-Oncology, 2013

731 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2187fd7e117cbc40b72aad69be0b79f0fd5cee6a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller

In Radiology, Nuclear Medicine and Imaging

1. Marion Smits
2. Martin Bendszus

Citations in the corpus

• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015, background): “Furthermore, very few therapeutic options exist for recurrent disease since patients with prior temozolomide exposure have progression-free survival (PFS) rates at 6 months of 20%–40% regardless of chemotherapeutic intervention (eg, nitrosoureas, temozolomide rechallenge, or bevacizumab).(5,6,8) Thu”
• Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020, background): “Treatment options at recurrence are limited, and no therapy has prolonged overall survival (OS) in this setting,whichunderscores theneed fornovel therapeutic interventions in thispatientpopulation.(4) Useof immunotherapy topromote antitumor immune response is an area of active research in the treatm”